Literature DB >> 16443219

Nuclear localisation of endogenous SUMO-1-modified PDGF-C in human thyroid tissue and cell lines.

Laila J Reigstad1, Aurora Martinez, Jan Erik Varhaug, Johan R Lillehaug.   

Abstract

We investigated post-translational modification and subcellular localisation of endogenous platelet-derived growth factor-C (PDGF-C) in human thyroid papillary carcinomas (PTC), non-neoplastic thyroid tissues, and a selection of cultured cell lines. PDGF-C expressed nuclear localisation in 95% of all tested cell types in culture and in 10% of the thyrocytes from both PTC and non-neoplastic tissue. The cell lines expressed two forms of full-length PDGF-C, approximately 39 and approximately 55 kDa, in cell membrane and cytosol, while the approximately 55 kDa form dominated in the nucleus where it was partly chromatin-associated. The approximately 55 kDa form was post-translationally modified by SUMO-1. The putative PDGF-C SUMOylation site is the surface exposed (314)lysine part of a positively charged loop ((312)RPKTGVRGLHK(322)) with characteristics of a nuclear localisation signal. The tissue thyrocytes expressed a non-SUMOylated approximately 43 kDa and the 55 kDa PDGF-C. The SUMO-1 modified approximately 55 kDa PDGF-C expression was low in PTC where the approximately 43 kDa PDGF-C dominated. This is in contrast to non-neoplastic tissue and cultured cells where the SUMOylated approximately 55 kDa PDGF-C was strongly expressed. Our data provide novel evidence for nuclear localisation of PDGF-C, post-translational modification by SUMOylation and the expression of a novel form of PDGF-C in human papillary thyroid carcinomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16443219     DOI: 10.1016/j.yexcr.2005.11.035

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

1.  The significance of SUMOylation of angiogenic factors in cancer progression.

Authors:  Mei Wang; Xiaodong Jiang
Journal:  Cancer Biol Ther       Date:  2018-09-27       Impact factor: 4.742

2.  An oncogenic activity of PDGF-C and its splice variant in human breast cancer.

Authors:  Alyssa Bottrell; Yong Hong Meng; Abdo J Najy; Newton Hurst; Seongho Kim; Chong Jai Kim; Eun-Sook Kim; Aree Moon; Eun Joo Kim; So Yeon Park; Hyeong-Reh Choi Kim
Journal:  Growth Factors       Date:  2019-09-23       Impact factor: 2.511

3.  The PDGF-C regulatory region SNP rs28999109 decreases promoter transcriptional activity and is associated with CL/P.

Authors:  Sun J Choi; Mary L Marazita; P Suzanne Hart; Pawel P Sulima; L Leigh Field; Toby Goldstein McHenry; Manika Govil; Margaret E Cooper; Ariadne Letra; Renato Menezes; Somnya Narayanan; Maria Adela Mansilla; José M Granjeiro; Alexandre R Vieira; Andrew C Lidral; Jeffrey C Murray; Thomas C Hart
Journal:  Eur J Hum Genet       Date:  2008-12-17       Impact factor: 4.246

Review 4.  Posttranslational Modifications in Thyroid Cancer: Implications for Pathogenesis, Diagnosis, Classification, and Treatment.

Authors:  Jordan M Broekhuis; Benjamin C James; Richard D Cummings; Per-Olof Hasselgren
Journal:  Cancers (Basel)       Date:  2022-03-22       Impact factor: 6.639

5.  Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas.

Authors:  Ove Bruland; Øystein Fluge; Lars A Akslen; Hans G Eiken; Johan R Lillehaug; Jan E Varhaug; Per M Knappskog
Journal:  BMC Cancer       Date:  2009-12-08       Impact factor: 4.430

Review 6.  Targeted Therapies in Liver Fibrosis: Combining the Best Parts of Platelet-Derived Growth Factor BB and Interferon Gamma.

Authors:  Fransien van Dijk; Peter Olinga; Klaas Poelstra; Leonie Beljaars
Journal:  Front Med (Lausanne)       Date:  2015-10-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.